ALKS – Alkermes plc
Alkermes plcALKS
$30.84Name : Alkermes plc
Sector : Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Mark. Cap: $5,085,546,496.00
EPSttm : 2.1
Alkermes plc
$30.84
1.38%$0.43Float Short %
7.95
Margin Of Safety %
-14
Put/Call OI Ratio
0.3
EPS Next Q Diff
0.36
EPS Last/This Y
-0.44
EPS This/Next Y
-0.01
Price
30.85
Target Price
39.57
Analyst Recom
1.87
Performance Q
-3.5
Relative Volume
0.58
Beta
0.48
Ticker: ALKS
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-04-14 | ALKS | 27.53 | 1.05 | 0.00 | 7170 |
| 2025-04-15 | ALKS | 27.95 | 0.99 | 0.00 | 7399 |
| 2025-04-16 | ALKS | 27.22 | 0.98 | 58.18 | 7408 |
| 2025-04-17 | ALKS | 27.01 | 0.42 | 0.00 | 5293 |
| 2025-04-18 | ALKS | 27 | 0.42 | 0.00 | 5293 |
| 2025-04-21 | ALKS | 27.01 | 0.18 | 0.27 | 3862 |
| 2025-04-22 | ALKS | 27.1 | 0.18 | 31.50 | 3875 |
| 2025-04-23 | ALKS | 27.11 | 0.24 | 3.92 | 4066 |
| 2025-04-24 | ALKS | 27.66 | 0.25 | 0.43 | 4116 |
| 2025-04-25 | ALKS | 27.84 | 0.25166767738023 | 0.23076923076923 | 4128 |
| 2025-04-28 | ALKS | 27.91 | 0.25181818181818 | 0.35714285714286 | 4131 |
| 2025-04-29 | ALKS | 28.69 | 0.25 | 0.54 | 4183 |
| 2025-04-30 | ALKS | 28.75 | 0.25 | 0.43 | 4186 |
| 2025-05-01 | ALKS | 30.56 | 0.26 | 0.34 | 4207 |
| 2025-05-02 | ALKS | 31.78 | 0.26 | 0.75 | 4309 |
| 2025-05-05 | ALKS | 31.41 | 0.26 | 0.10 | 4323 |
| 2025-05-06 | ALKS | 30.37 | 0.26 | 0.17 | 4323 |
| 2025-05-07 | ALKS | 30.37 | 0.26 | 0.06 | 4289 |
| 2025-05-08 | ALKS | 30.36 | 0.26 | 28.00 | 4291 |
| 2025-05-09 | ALKS | 30.12 | 0.28 | 4.00 | 4347 |
| 2025-05-12 | ALKS | 31.28 | 0.28 | 9.25 | 4359 |
| 2025-05-13 | ALKS | 30.84 | 0.30 | 0.24 | 4427 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-04-14 | ALKS | 27.54 | -37.5 | -164.9 | 1.79 |
| 2025-04-15 | ALKS | 27.94 | -43.4 | -166.8 | 1.79 |
| 2025-04-16 | ALKS | 27.22 | -44.3 | -180.7 | 1.79 |
| 2025-04-17 | ALKS | 27.00 | -44.3 | -174.4 | 1.79 |
| 2025-04-18 | ALKS | 27.00 | -44.3 | -171.8 | 1.79 |
| 2025-04-21 | ALKS | 27.01 | -44.3 | -171.7 | 1.79 |
| 2025-04-22 | ALKS | 27.11 | -44.3 | -170.4 | 1.79 |
| 2025-04-23 | ALKS | 27.15 | -44.3 | -171.3 | 1.79 |
| 2025-04-24 | ALKS | 27.67 | -44.3 | -165.2 | 1.79 |
| 2025-04-25 | ALKS | 27.84 | -44.3 | -169.7 | 1.79 |
| 2025-04-28 | ALKS | 27.91 | -44.3 | -170.9 | 1.79 |
| 2025-04-29 | ALKS | 28.77 | -44.3 | -161.2 | 1.79 |
| 2025-04-30 | ALKS | 28.77 | -43.1 | -172.1 | 1.79 |
| 2025-05-01 | ALKS | 30.58 | -43.1 | -149.7 | 1.79 |
| 2025-05-02 | ALKS | 31.78 | -43.1 | -158.5 | 1.79 |
| 2025-05-05 | ALKS | 31.39 | -38.3 | -176.1 | 1.77 |
| 2025-05-06 | ALKS | 30.36 | -40.3 | -156.0 | 1.78 |
| 2025-05-07 | ALKS | 30.38 | -40.3 | -144.1 | 1.78 |
| 2025-05-08 | ALKS | 30.36 | -40.3 | -144.6 | 1.78 |
| 2025-05-09 | ALKS | 30.13 | -40.3 | -147.3 | 1.78 |
| 2025-05-12 | ALKS | 31.27 | -40.3 | -131.1 | 1.78 |
| 2025-05-13 | ALKS | 30.85 | -40.3 | -149.1 | 1.78 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-04-14 | ALKS | -12.76 | -6.50 | 6.85 |
| 2025-04-15 | ALKS | -12.76 | -6.50 | 6.85 |
| 2025-04-16 | ALKS | -12.76 | -6.50 | 6.85 |
| 2025-04-17 | ALKS | -12.76 | -6.50 | 6.85 |
| 2025-04-18 | ALKS | -12.76 | -6.50 | 6.85 |
| 2025-04-21 | ALKS | -12.76 | -6.47 | 6.85 |
| 2025-04-22 | ALKS | -12.71 | -6.47 | 6.85 |
| 2025-04-23 | ALKS | -12.71 | -6.47 | 6.85 |
| 2025-04-24 | ALKS | -12.71 | -6.47 | 6.85 |
| 2025-04-25 | ALKS | -12.71 | -6.47 | 6.85 |
| 2025-04-28 | ALKS | -12.71 | -6.47 | 7.69 |
| 2025-04-29 | ALKS | -12.71 | -6.47 | 7.69 |
| 2025-04-30 | ALKS | -12.71 | -6.47 | 7.69 |
| 2025-05-01 | ALKS | -12.71 | -6.47 | 7.69 |
| 2025-05-02 | ALKS | -12.71 | -6.47 | 7.69 |
| 2025-05-05 | ALKS | -12.71 | -7.31 | 7.69 |
| 2025-05-06 | ALKS | -12.71 | -7.31 | 7.69 |
| 2025-05-07 | ALKS | -12.52 | -7.31 | 7.69 |
| 2025-05-08 | ALKS | -12.52 | -7.31 | 7.69 |
| 2025-05-09 | ALKS | -12.52 | -7.31 | 7.69 |
| 2025-05-12 | ALKS | -12.52 | -7.38 | 7.95 |
| 2025-05-13 | ALKS | -11.45 | -7.38 | 7.95 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
0.13
Avg. EPS Est. Current Quarter
0.42
Avg. EPS Est. Next Quarter
0.49
Insider Transactions
-11.45
Institutional Transactions
-7.38
Beta
0.48
Average Sales Estimate Current Quarter
342
Average Sales Estimate Next Quarter
355
Fair Value
26.39
Quality Score
99
Growth Score
47
Sentiment Score
68
Actual DrawDown %
15.4
Max Drawdown 5-Year %
-33.2
Target Price
39.57
P/E
14.68
Forward P/E
17.52
PEG
P/S
3.36
P/B
3.36
P/Free Cash Flow
10.56
EPS
2.1
Average EPS Est. Cur. Y
1.78
EPS Next Y. (Est.)
1.77
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
23.3
Relative Volume
0.58
Return on Equity vs Sector %
-0.4
Return on Equity vs Industry %
15.7
EPS 1 7Days Diff
EPS 1 30Days Diff
-0.06
EBIT Estimation
-149.1
Alkermes plcSector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Employees: 1800
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
stock quote shares ALKS – Alkermes plc Stock Price stock today
news today ALKS – Alkermes plc stock forecast ,stock prediction 2023 2024 2025
marketwatch ALKS – Alkermes plc yahoo finance google finance
stock history ALKS – Alkermes plc invest stock market
stock prices ALKS premarket after hours
ticker ALKS fair value insiders trading